Some theories suggest, that bradykinin may play a role in pathogenesis of tissue damage in COVID-19 infection. It is also a main mediator responsible for angioedema attacks in patients with hereditary angioedema.
Therefore we may assume COVID-19 infection can be more severe for these patients. Unfortunately we have only limited data about course of COVID-19 disease in hereditarian angioedema patients so far.
However, angioedema without wheals has been described in patients with COVID-19 infection and some trials showed improvement of COVID-19 pneumonia after administration of drugs, commonly used for angioedema treatment. These findings may support bradykinin involvement in COVID-19 tissue damage.